Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.","authors":"Wei Lu, Zhiyuan Li, Chen Pan, Bingliang Chen, Gang Zhang, Zhiming Yang, Jingcheng Hao","doi":"10.1007/s00432-025-06233-7","DOIUrl":"https://doi.org/10.1007/s00432-025-06233-7","url":null,"abstract":"<p><strong>Introduction: </strong>Transarterial chemoembolization (TACE), anti-angiogenic drugs (AADs), and immune checkpoint inhibitors (ICIs) are common therapies for hepatocellular carcinoma (HCC). Despite proven benefits of combined regimens, optimal sequencing remains unclear. This network meta-analysis evaluates safety and efficacy of therapeutic sequences in intermediate-advanced HCC.</p><p><strong>Methods: </strong>We conducted a comprehensive search of multiple databases, including PubMed, Cochrane Library, Web of Science, and EMBASE, for studies published until February 1, 2025. Cochrane's tools and the Newcastle-Ottawa Scale were used to assess the evaluation of bias. We performed data compilation and conducted a network meta-analysis to compare the relative efficacy of different treatments.</p><p><strong>Results: </strong>A total of 56 studies (10,456 patients) evaluated 11 therapeutic sequences. Survival outcomes favored TACE-AADs-ICIs (TAI), which ranked highest for overall survival (OS: SUCRA 90.0%) and progression-free survival (PFS: SUCRA 91.3%). Tumor responses differed significantly across regimens: TACE-ICIs (TI) achieved the highest probability of complete response rate (CRR: SUCRA 83.9%), while AADs-ICIs-TACE (AIT) ranked first in objective response rate (ORR: SUCRA 85.8%). Notably, ICIs-AADs (IA) achieved superior disease control rate (DCR: SUCRA 88.1%). ICIs monotherapy (I) was associated with the lowest incidence of grade ≥ 3 adverse events (AEs: SUCRA 11.7%).</p><p><strong>Conclusion: </strong>Our comprehensive network meta-analysis establishes a multidimensional efficacy-safety profile for sequential therapies in intermediate and advanced HCC management. TACE-initiated sequences (TAI/TIA) optimize survival (OS/PFS: SUCRA > 90%), while systemic-first regimens (AIT/IA) maximize tumor response (ORR/DCR: SUCRA > 85%). ICIs monotherapy exhibits the safest profile. Further clinical studies are warranted to determine optimal treatment sequencing for intermediate and advanced HCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"196"},"PeriodicalIF":2.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review.","authors":"Rosenfeld Roberto, Sganga Stefano, Badalamenti Marco, Mortellaro Sveva, Scorsetti Marta, Garrone Ornella, Iannantuono Giovanni Maria, Chandran Elias, Ghidini Michele, Franzese Ciro","doi":"10.1007/s00432-025-06245-3","DOIUrl":"https://doi.org/10.1007/s00432-025-06245-3","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) has been considered an immunologically \"cold tumor\". Indeed, in advanced PCa, immune checkpoint inhibitors (ICIs) or anti-tumor vaccines have shown poor results in phase II and phase III trials with the exception of sipuleucel-T that showed a modest survival benefit. Radiotherapy and Targeted radioisotopes, such as ²²³Radium or ¹⁷⁷Lu-PSMA-617 monotherapy, contributed in prolonging the progression-free survival of PCa patients in second or third line. However, potential benefits of combination with immune therapies were inconstantly investigated and outcomes often were discordant.</p><p><strong>Objective: </strong>Aim of this systematic review was to gather and analyze clinical evidence about benefits and risks of combining ionizing-radiation-based treatments with the main immunotherapies administed in clinical and experimental oncology for the setting of metastatic PCa.</p><p><strong>Methods: </strong>We performed a systematic review according to the PRISMA-ScR criteria, investigating PubMed, Web of science, Embase and Medline databases from February 2000 to April 2024, searching for phase I to phase III clinical trials associating radiotherapy with immunotherapy (RT/IT) in metastatic PCa patients.</p><p><strong>Conclusion: </strong>We observed that combination of Ipilimumab with stereotactic beam radiotherapy (SBRT) at the dose of 8 Gy performed about 12 days (range 2-21) before immunotherapy was liked with trials with a significative gain in progression-free survival. Furtherly, we described better objective responses when immunotherapies, were associated with SBRT than radionuclides An exception was ¹⁷⁷Lu-PSMA-617, which showed promising synergic results after few cycles of standard doses, suggesting a possible enhancing of immune system, in particular when associated with anti-PD1 (pembrolizumab). Due to the few data reported in literature, both for radiotherapy and radionuclides, however, future randomized trials should confirm these data.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"195"},"PeriodicalIF":2.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML.","authors":"Mohamed J Saadh, Nima Torabi Fard, Ahmed Hussein, Amirhossein Mirzazadeh, Mohammad Siavashi, Fatemeh SeyedMoharami, Shekoofeh Noroozi, Hamed Soleimani Samarkhazan","doi":"10.1007/s00432-025-06244-4","DOIUrl":"10.1007/s00432-025-06244-4","url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) play a pivotal role in supporting acute myeloid leukemia (AML) cell survival, proliferation, and drug resistance through various mechanisms, including the release of soluble factors, direct cell-cell interactions, and the creation of a leukemia-supportive niche. Conversely, MSCs also demonstrate potential inhibitory effects on AML, including the induction of apoptosis, cell cycle arrest, and the modulation of immune responses. These contrasting effects highlight the complexities of MSC-AML interactions and emphasize the need for further research to understand their therapeutic potential fully. Targeting MSCs represents a promising avenue for AML treatment. Strategies aimed at modifying MSC-mediated support of AML cells, such as inhibiting pro-survival signaling pathways, disrupting the leukemia-supportive niche, and enhancing the immune-stimulatory functions of MSCs, could offer novel therapeutic approaches. However, it is essential to acknowledge the limitations of current research. Further investigations are necessary to elucidate the precise mechanisms underlying the dual effects of MSCs in AML, to identify biomarkers that predict patient response to MSC-targeted therapies, and to develop strategies to overcome potential challenges associated with MSC-based interventions. In conclusion, understanding the multifaceted role of MSCs in AML pathogenesis is crucial for developing innovative therapeutic approaches. By harnessing the potential of MSCs and targeting their interactions with AML cells, we can explore novel strategies to improve treatment outcomes and enhance the overall management of this challenging hematological malignancy. This review underscores the intricate relationship between MSCs and AML within the bone marrow microenvironment.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"193"},"PeriodicalIF":2.7,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autophagy-related biological targets and network mechanisms of juglone against bladder cancer.","authors":"Yuanfeng Zhang, Enguang Yang, Xinyu Zhang, Ze Zhang, Guoxin Huang, Baoyuan Tang, Chaohu Chen, Longhui Lai, Zixu Pei, Yonghai Zhang, Zhiping Wang","doi":"10.1007/s00432-025-06243-5","DOIUrl":"10.1007/s00432-025-06243-5","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore juglone's mechanism in inducing autophagy and apoptosis in bladder cancer (BLCA) via network pharmacology and experimental validation.</p><p><strong>Methods: </strong>Juglone's effects on BLCA cell proliferation, apoptosis, and autophagy were assessed using CCK-8, flow cytometry, transmission electron microscopy, and Western blotting. Network pharmacology, molecular docking, and dynamics simulations identified key targets. In vivo validation employed H&E, immunohistochemical, and TUNEL staining.</p><p><strong>Results: </strong>Juglone suppressed T24 and UMUC-3 cell proliferation, enhanced autophagy markers, and induced apoptosis. Network analysis identified 108 shared targets, with AKT1, CASP3, and TP53 as core nodes. Pathway enrichment implicated the PI3K/Akt signalling pathway, supported by molecular docking. Autophagy inhibition reduced juglone-induced apoptosis, confirming autophagic death's role.</p><p><strong>Conclusions: </strong>Juglone triggers BLCA autophagy via PI3K/AKT/mTOR, upregulates apoptotic proteins, and activates caspase 3, promoting apoptosis.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"194"},"PeriodicalIF":2.7,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study.","authors":"Andreas Schneeweiss, Peter A Fasching, Marc Thill, Marion van Mackelenbergh, Frederik Marme, Hans Tesch, Tanja N Fehm, Tjoung-Won Park-Simon, Lothar Häberle, Sabrina Uhrig, Oliver Tome, Thomas Spall, Anna-Katharin Theuser, Matthias Ruebner, Erik Belleville, Diethelm Wallwiener, Sara Y Brucker, Andreas D Hartkopf","doi":"10.1007/s00432-025-06246-2","DOIUrl":"10.1007/s00432-025-06246-2","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapies are still widely used in advanced breast cancer, specifically in patients with HER2-negative disease. This non-interventional real-world study assessed the utilization of nab-paclitaxel in a broad patient population with advanced breast cancer.</p><p><strong>Methods: </strong>SERAPHINA (NCT02642406) was a single arm, non-interventional study performed in Germany. Patients were eligible if they were treated with nab-paclitaxel according to the Summary of Product Characteristics (SmPC) as indicated by their physician. Progression-free survival (PFS), overall survival (OS), safety and quality of life were evaluated. Additionally, efficacy was assessed in patient subgroups based on age, metastasis pattern, performance status and therapy line.</p><p><strong>Results: </strong>A total of 432 patients were treated with nab-paclitaxel. The majority of patients had HER2-negative disease (94.2%). Furthermore, 30.1% of patients were treated in the first line and 48.3% in the third or later therapy line. Median PFS was 6.0 months (95% CI: 5.6-6.9) and median OS was 15.3 months (95% CI: 12.5-17.5). Although no clear predictors of PFS and OS in multivariable Cox models could be identified, patients with brain metastases had the shortest PFS (3.0 months; 95% CI: 2.2-4.3). Adverse events occurred in 83.1% of patients, with high-grade adverse events being rare (< 8% of patients). Quality of life did not change under therapy.</p><p><strong>Conclusion: </strong>Nab-paclitaxel is used in patients with advanced breast cancer. In this real-world, non-interventional study, prognosis was favorable and safety profile manageable, which is comparable to previous clinical trials and real-world studies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"192"},"PeriodicalIF":2.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population.","authors":"Florian Gerhardt, Christian Müller, Marino Venerito, Jack Chater, Raphael Mohr, Mara Egerer, Udo Lindig, Aaron Schindler, Sebastian Ebel, Janett Fischer, Maik Schwarz, Sonja Gehring, Thomas Berg, Florian van Bömmel","doi":"10.1007/s00432-025-06239-1","DOIUrl":"10.1007/s00432-025-06239-1","url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancers (BTCs) are a heterogeneous group of malignant cancers with an overall poor prognosis. For more than a decade, the standard palliative first-line therapy was cytotoxic chemotherapy with gemcitabine/cisplatin. The results of the TOPAZ-1 and KEYNOTE-966 trials have now introduced immune checkpoint inhibitors (ICIs) into first-line therapy.</p><p><strong>Methods: </strong>Between July 2022 and March 2024, we retrospectively analyzed patients with advanced BTC who were treated with gemcitabine/cisplatin and durvalumab (GCD) at collaborating German university hospitals, tertiary hospitals, and outpatient oncology practices.</p><p><strong>Results: </strong>A total of 90 patients were enrolled. The median overall survival (mOS) was 16 months, and the median progression-free survival (mPFS) was 5 months. The overall response rate (ORR) was 11.1%, and the disease control rate (DCR) was 41.1%. A perihilar primary tumor was significantly associated with better mPFS, while age group between 70 and 75 years and performance status of ECOG 2 at treatment initiation were significantly associated with poorer mOS. Adverse events (AEs) occurred in a total of 64% of patients. The most common grade 1 and grade 2 AEs included anemia (23%), thrombocytopenia (16%), neutropenia (10%), nausea (14%), and fatigue (16%). Grade 3 and grade 4 AEs included anemia (10%), thrombocytopenia (5%), and neutropenia (11%). Only one case of immune-mediated hypothyroidism (imAE) was documented.</p><p><strong>Conclusion: </strong>Our real-world data support previously reported findings and further validate ICI based therapy as the standard of care for patients with advanced BTCs.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"191"},"PeriodicalIF":2.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and interpretation of machine learning-based prognostic models for predicting high-risk prognostic pathological components in pulmonary nodules: integrating clinical features, serum tumor marker and imaging features.","authors":"Dingxin Wang, Jianhao Qiu, Rongyang Li, Hui Tian","doi":"10.1007/s00432-025-06241-7","DOIUrl":"10.1007/s00432-025-06241-7","url":null,"abstract":"<p><strong>Background: </strong>With the improvement of imaging, the screening rate of Pulmonary nodules (PNs) has further increased, but their identification of High-Risk Prognostic Pathological Components (HRPPC) is still a major challenge. In this study, we aimed to build a multi-parameter machine learning predictive model to improve the discrimination accuracy of HRPPC.</p><p><strong>Method: </strong>This study included 816 patients with ≤ 3 cm pulmonary nodules with clear pathology and underwent pulmonary resection. High-resolution chest CT images, clinicopathological characteristics were collected from patients. Lasso regression was utilized in order to identify key features, and a machine learning prediction model was constructed based on the screened key features. The recognition ability of the prediction model was evaluated using (ROC) curves and confusion matrices. Model calibration ability was evaluated using calibration curves. Decision curve analysis (DCA) was used to evaluate the value of the model for clinical applications. Use SHAP values for interpreting predictive models.</p><p><strong>Result: </strong>A total of 816 patients were included in this study, of which 112 (13.79%) had HRPPC of pulmonary nodules. By selecting key variables through Lasso recursive feature elimination, we finally identified 13 key relevant features. The XGB model performed the best, with an area under the ROC curve (AUC) of 0.930 (95% CI: 0.906-0.954) in the training cohort and 0.835 (95% CI: 0.774-0.895) in the validation cohort, indicating that the XGB model had excellent predictive performance. In addition, the calibration curves of the XGB model showed good calibration in both cohorts. DCA demonstrated that the predictive model had a positive benefit in general clinical decision-making. The SHAP values identified the top 3 predictors affecting the HRPPC of PNs as CT Value, Nodule Long Diameter, and PRO-GRP.</p><p><strong>Conclusion: </strong>Our prediction model for identifying HRPPC in PNs has excellent discrimination, calibration and clinical utility. Thoracic surgeons could make relatively reliable predictions of HRPPC in PNs without the possibility of invasive testing.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"190"},"PeriodicalIF":2.7,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system.","authors":"Chris Wynne, Bei Wang, Rong Deng, Junyi Li, Daniel Eiger, Fabiola Bene Tchaleu, Sarah Heeson, Eleonora Restuccia","doi":"10.1007/s00432-025-06228-4","DOIUrl":"10.1007/s00432-025-06228-4","url":null,"abstract":"<p><strong>Purpose: </strong>This randomized, open-label, two-arm, parallel-group, single dose, multi-center phase I study (ClinicalTrials.gov ID, NCT05275010) investigated the comparability of the pharmacokinetics of a new formulation combining pertuzumab (P) and trastuzumab (H) in one fixed-dose combination for subcutaneous injection (FDC SC) using a proprietary on-body injector (OBI) or a handheld syringe with hypodermic needle in healthy male subjects.</p><p><strong>Methods: </strong>Healthy male subjects were randomized 1:1 to either PH FDC SC using a handheld syringe (Arm 1) or an OBI device (Arm 2). Co-primary endpoints were: (i) area under the time-concentration curve (AUC) from the start of dosing to day 63 (AUC_0-62) of serum P, (ii) maximum serum concentration (C_max) from start of dosing to 63 days of serum P, (iii) AUC from the start of dosing to day 63 (AUC_0-62) of serum H, and (iv) C_max from start of dosing to 63 days of serum H. Safety was a key secondary endpoint. Liquid chromatography coupled to tandem mass spectrometry was used to measure pertuzumab and trastuzumab simultaneously in serum samples.</p><p><strong>Results: </strong>The obtained geometric mean ratios for C_max and AUC_0-62 were within the pre-specified bioequivalence margins (0.80, 1.25) for both P and H, therefore meeting the criteria for bioequivalence. No discontinuations due to safety reasons were reported. Overall, the final safety analysis with longer follow-up was consistent with the primary analysis; there were no new or unexpected safety findings.</p><p><strong>Conclusion: </strong>This study demonstrated the feasibility of a hands-free device approach to deliver pertuzumab and trastuzumab in one fixed-dose combination for subcutaneous injection without compromising pharmacokinetics and safety.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"188"},"PeriodicalIF":2.7,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sit to stand is a new reliable method for assessing strength, power, and velocity exercise in adult pediatric cancer survivors.","authors":"Ángela Rodríguez-Perea, Daniel Jerez-Mayorga, Esther Ubago-Guisado, Andres Marmol-Perez, Daniel Jiménez-Lupión, Andrea Rodríguez-Solana, Luis Javier Chirosa Rios, Francisco J Llorente-Cantarero, María Herrada-Robles, Luis Gracia-Marco","doi":"10.1007/s00432-025-06225-7","DOIUrl":"10.1007/s00432-025-06225-7","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to analyze the intra-set reliability of 5 sit-to-stand (5-STS) exercises with a functional electromechanical dynamometer (FEMD) and to determine and compare the load-velocity (L-V) profile in the STS exercise in adult pediatric cancer survivors by sex, age, body mass index, and type and treatment of cancer.</p><p><strong>Method: </strong>A total of 47 participants performed the 5-STS test with 5% and 20% body weight (BW) to assess intrasession reliability and analyze differences in L-V profiles by sex, age, BMI, and type and treatment of cancer.</p><p><strong>Results: </strong>Very high and extremely high relative reliability was found for both the 5% STS (ICC = 0.80-0.94) and the 20% STS (ICC = 0.87-0.95) relate to average and peak force, power, and velocity. Regarding L-V profiles, significant differences were only found in relation to sex for the velocity-axis intercept and area under the line (p < 0.05).</p><p><strong>Conclusion: </strong>The 5-STS test with a load of 5% and 20% of BW using a FEMD is a reliable method for assessing strength, power, and velocity exercise in adult pediatric cancer survivors. There was a relation to sex for the variables of L-V profile.</p><p><strong>Implications for cancer survivors: </strong>Reliable assessments of muscular strength, like the 5-STS test using FEMD, offer a safer, less demanding alternative to maximal strength tests (e.g., 1RM), enabling precise intensity control and better-tailored rehabilitation programs.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"189"},"PeriodicalIF":2.7,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to breast cancer recurrence and associated predictors in Public Hospitals of Addis Ababa, Central Ethiopia: a retrospective Cohort Study.","authors":"Yadessa Chala, Tesfaye Techane, Bonsisa Bekele, Tesfaye Girma, Warati Fekede, Chalchisa Abdeta, Kibiru Mardasa, Tolera Abdeta, Bedada Teshome, Gashaye Atinkut, Abdinasir Wako, Mohammed Adem, Alem Deksisa","doi":"10.1007/s00432-025-06181-2","DOIUrl":"10.1007/s00432-025-06181-2","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer recurrence is a significant concern when the disease returns following surgery. The time to recurrence and factors affecting it are not well studied in low-income countries. This study aimed to assess the time to recurrence and predictors of breast cancer among women treated in public hospitals of Addis Ababa, Ethiopia.</p><p><strong>Methods: </strong>Retrospective cohort study was conducted from April 30 to May 30, 2024, among randomly selected 322 recorded cases. The study covered from September 11, 2018, to September 12, 2023. Data were collected by the Kobo toolbox and analyzed by Stata Version 15. The Cox proportional hazard model was used to identify predictor variables, with assumptions checked using the Schoenfeld residual/global test (0.79). Multi-collinearity was checked using the variance inflation factor (3.72). Variables with a P-value < 0.25 in bivariable analysis were entered into the final multivariable analysis. Variables with a P-value < 0.05 at 95% confidence level were considered independent predictors of recurrence.</p><p><strong>Result: </strong>The recurrence-free survival (RFS) status at the median follow-up time was 87.5%. The incidence rate of breast cancer recurrence was 6.8 per 100 women years (95%CI = 5.34-8.13) follow-up. The 75%RFS time was 44 months (95CI% = 40-48). The proportion of RFS survival at 24, 36, 48, and 60 months was 91.93%, 83.3%, and 67.7%, 61% respectively. Women aged 40 & below (AHR = 3.32; 95%CI 1.80-5.88), Overweight (AHR = 1.95, 95%CI 1.06 -3.59), surgical margin positive (AHR = 2.1; 95%CI 1.20-4.02), axillary node-positive (AHR = 1.98; 95%CI 1.08-3.61) and comorbidity (AHR = 4.45, 95%CI 2.39-8.30) were independent predictors for increased hazard of recurrence.</p><p><strong>Conclusion: </strong>This study confirms a substantial incidence of breast cancer recurrence, with identifiable predictors including comorbidity, age, overweight, positive axillary node status, lymph node involvement, and deep surgical margin. Targeted interventions aimed at improving patient understanding of recurrence risk, promoting adherence to treatment protocols, and fostering healthy lifestyle modifications are crucial for reducing recurrence rates.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"187"},"PeriodicalIF":2.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}